There is a high unmet treatment need for novel oral LDL-c lowering therapies to be used on top of statins. Can CETP inhibition innovate the clinical management of LDL-c? In this series, three experts review the history on CETP inhibition, explain what we have learned from clinical trials with CETP inhibitors and explore recent data of a novel CETP inhibitor.
This course consists of 3 episodes. Watch all episodes, answer pre- and post-test questions, and start earning CME credits.
This educational program consists of 3 presentations on CETP inhibition.
What do we know now that could have changed the history of CETP Inhibition?: genetics and biology - John Kastelein, MD, PhD - Amsterdam, The Netherlands
CETP inhibition: Lessons from two decades of clinical trials- Stephen Nicholls, MD – Melbourne, Australia
A novel CETP-inhibitor to target CV risk reduction: Where could it fit in future lipid management?- Erin Michos, MD - Baltimore, MD, US
For questions regarding this activity, please contact us at info@pace-cme.org.
This educational activity is designed for all healthcare professionals with an interest in management of patients with hyperlipidemia.
This enduring activity is accredited by the European Board for Accreditation of Continuing Education for Health Professional (EBAC) for 35 minutes of effective education time.
Through an agreement between EBAC and the American Medical Association, physicians may convert EBAC External CME credits to AMA PRA Category 1 Credits™. Information on the process to convert EBAC credit to AMA credit can be found on the AMA website. Other health care professionals may obtain from the AMA a certificate of having participated in an activity eligible for conversion of credit to AMA PRA Category 1 Credit™.
Today’s healthcare environment is constantly evolving and advances of medical science occur at an accelerating pace. CME/CE plays an important role in the clinical environment and is an essential element of physician training, learning, and improvement, thereby importantly contributing to optimal patient care. Since 2000, MEDCON’s mission is to deliver high quality within the world of medical education by creating forums like PACE-CME, organizing live meetings, and providing online education. We aim to stimulate the review, exchange, and assimilation of key scientific findings to improve patients’ health, to raise awareness of new science underlying various disease states, and to accelerate the translation of this information into clinical practice.
Funding for this educational program was provided by an unrestricted educational grant from NewAmsterdam Pharma.
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of PACE-CME.
Release Date:
Expiration Date:
